Previous studies of Kv1.3 in MS and other neuroinflammatory diseases were mainly focused on the ionic immune regulating role of Kv1.3 in T cells (Rus et al., 2005; Schmitz et al., 2005; Eil et al., 2016; Wang et al., 2019) and microglia (Fordyce et al., 2005; Di Lucente et al., 2018), which were relative to the pathogenesis in relapsing–remitting phase. This evidence concerns the gene KCNA3 and myeloid sarcoma.